Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy.
CCI
Charlson comorbidity index
Comorbidity
Limited disease
SCLC
Small cell lung cancer
Survival
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
22
04
2023
revised:
03
07
2023
accepted:
22
07
2023
medline:
11
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
Combined, platinum-based thoracic chemoradiotherapy (TCR) is the current state-of-the-art treatment for patients with limited disease (LD) small-cell lung cancer (SCLC). There is only limited data available regarding the effect of comorbidities on survival following TRC. The purpose of this study is to assess the age-adjusted Charlson comorbidity index (ACCI) as a predictor of overall survival in LD-SCLC patients undergoing TCR. We retrospectively analyzed 367 SCLC patients diagnosed with LD-SCLC who received TCR between 2003 and 2017. We evaluated the ACCI (n = 348) as a predictor of overall survival (OS). In this cohort, 322 patients (88%) received platinum-based TCR (either cisplatin or carboplatin), and 37 (10%) patients received vincristine based TCR. Median radiation dose was 60 Gy (range 24-66 Gy). Additionally, 83% of patients (n = 303) received prophylactic cranial irradiation (PCI, 30 Gy in 2 Gy fractions). Kaplan-Meier survival analysis was performed for OS. For comparison of survival curves, Log-rank (Mantel-Cox) test was used. Univariate and multivariate Cox proportional-hazards ratios (HRs) were used to assess the influence of cofactors on OS. Patients with an ACCI > 6 had a significantly shorter OS compared with patients with an ACCI ≤ 6 (median 11 vs. 20 months; p = 0.005). Univariate analysis for OS revealed a statistically significant effect for ACCI > 6 (HR 1.7; 95% CI 1.2-2.4; p = 0.003), PCI (HR 0.5; 95% CI 0.3-0.7; p < 0.001), and Karnofsky performance status ≤ 70% (KPS) (HR 1.4; 95% CI 1.1-1.90; p = 0.015). In multivariate analysis, OS was significantly associated with PCI (HR 0.6; 95% CI 0.4-0.9; p = 0.022) and ACCI > 6 (HR 1.5; 95% CI 1.0-2.1; p = 0.049). Comorbidity is significantly associated with survival in patients with LD-SCLC undergoing TCR. The ACCI may be a valuable tool to identify patients with a shorter survival and thus might be used for risk stratification and oncological decision making.
Sections du résumé
Background
UNASSIGNED
Combined, platinum-based thoracic chemoradiotherapy (TCR) is the current state-of-the-art treatment for patients with limited disease (LD) small-cell lung cancer (SCLC). There is only limited data available regarding the effect of comorbidities on survival following TRC. The purpose of this study is to assess the age-adjusted Charlson comorbidity index (ACCI) as a predictor of overall survival in LD-SCLC patients undergoing TCR.
Patients and methods
UNASSIGNED
We retrospectively analyzed 367 SCLC patients diagnosed with LD-SCLC who received TCR between 2003 and 2017. We evaluated the ACCI (n = 348) as a predictor of overall survival (OS). In this cohort, 322 patients (88%) received platinum-based TCR (either cisplatin or carboplatin), and 37 (10%) patients received vincristine based TCR. Median radiation dose was 60 Gy (range 24-66 Gy). Additionally, 83% of patients (n = 303) received prophylactic cranial irradiation (PCI, 30 Gy in 2 Gy fractions). Kaplan-Meier survival analysis was performed for OS. For comparison of survival curves, Log-rank (Mantel-Cox) test was used. Univariate and multivariate Cox proportional-hazards ratios (HRs) were used to assess the influence of cofactors on OS.
Results
UNASSIGNED
Patients with an ACCI > 6 had a significantly shorter OS compared with patients with an ACCI ≤ 6 (median 11 vs. 20 months; p = 0.005). Univariate analysis for OS revealed a statistically significant effect for ACCI > 6 (HR 1.7; 95% CI 1.2-2.4; p = 0.003), PCI (HR 0.5; 95% CI 0.3-0.7; p < 0.001), and Karnofsky performance status ≤ 70% (KPS) (HR 1.4; 95% CI 1.1-1.90; p = 0.015). In multivariate analysis, OS was significantly associated with PCI (HR 0.6; 95% CI 0.4-0.9; p = 0.022) and ACCI > 6 (HR 1.5; 95% CI 1.0-2.1; p = 0.049).
Conclusion
UNASSIGNED
Comorbidity is significantly associated with survival in patients with LD-SCLC undergoing TCR. The ACCI may be a valuable tool to identify patients with a shorter survival and thus might be used for risk stratification and oncological decision making.
Identifiants
pubmed: 37564923
doi: 10.1016/j.ctro.2023.100665
pii: S2405-6308(23)00090-3
pmc: PMC10410177
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100665Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1079-85
pubmed: 26065838
Transl Lung Cancer Res. 2021 Apr;10(4):2071-2078
pubmed: 34012815
Clin Lung Cancer. 2013 Nov;14(6):644-50
pubmed: 23886797
Lung Cancer. 2013 Nov;82(2):358-61
pubmed: 24051083
Lung Cancer. 2015 Apr;88(1):85-93
pubmed: 25704956
Clin Lung Cancer. 2015 Jul;16(4):282-91
pubmed: 25572007
Oncotarget. 2017 Jun 7;8(45):79453-79461
pubmed: 29108324
Cancer. 2008 Jun;112(11):2384-92
pubmed: 18404699
J Thorac Oncol. 2011 Feb;6(2):378-83
pubmed: 21173715
Lung. 2015 Apr;193(2):291-7
pubmed: 25516286
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
J Am Geriatr Soc. 1994 Jan;42(1):64-70
pubmed: 8277118
Clin Lung Cancer. 2016 May;17(3):205-213.e1
pubmed: 26589440
N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
Clin Lung Cancer. 2015 Jul;16(4):305-12
pubmed: 25659438
Lung Cancer. 2015 Feb;87(2):186-92
pubmed: 25498829
J Clin Oncol. 2008 Jan 1;26(1):54-9
pubmed: 18165640
Heart. 2014 Feb;100(4):288-94
pubmed: 24186563
Cancer. 2013 Nov 1;119(21):3753-60
pubmed: 23921891
Br J Cancer. 2005 Nov 14;93(10):1098-105
pubmed: 16234816
PLoS One. 2014 Dec 03;9(12):e112479
pubmed: 25469987
Int J Cancer. 2013 May 1;132(9):2157-63
pubmed: 23015513
PLoS One. 2018 Jun 20;13(6):e0199365
pubmed: 29924851
Acta Oncol. 2016 Nov;55(11):1349-1354
pubmed: 27549509
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Urol Oncol. 2014 Jan;32(1):36.e27-34
pubmed: 23685020
Crit Rev Oncol Hematol. 2007 May;62(2):172-8
pubmed: 17197191
Medicine (Baltimore). 2015 Jan;94(2):e431
pubmed: 25590852
Lung. 2016 Apr;194(2):295-8
pubmed: 26883133
J Clin Oncol. 2004 Dec 15;22(24):4971-8
pubmed: 15611512
Occup Med (Lond). 2008 May;58(3):226-7
pubmed: 18441368
PLoS One. 2015 Jan 24;10(1):e0117323
pubmed: 25617629
Cancer Chemother Rep 3. 1973 Mar;4(2):31-42
pubmed: 4580860
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1321-30
pubmed: 12654444
J Thorac Oncol. 2018 Jan;13(1):54-62
pubmed: 29056534
J Clin Oncol. 2006 Oct 1;24(28):4526-7
pubmed: 17008688
J Thorac Oncol. 2016 May;11(5):748-757
pubmed: 26851495
Cancer Manag Res. 2018 Nov 30;10:6563-6569
pubmed: 30555261